Research
Hormonal
Melanin-concentrating hormone (MCH) neurons in the LHA promote feeding and general intake behavior, while their blockade can increase energy expenditure and promote weight loss.
Research into MCH receptors shows potential for treating obesity by reducing food intake and increasing energy expenditure. However, current treatments are not yet available for humans, and lifestyle changes remain the primary strategy.
GoodSupportsHIGH confidence
Central injection of MCH into the brain increases feeding in rodents and promotes obesity thus it is considered an orexigenic neuropeptide... Blocking acute action of MCHR-1 via selective antagonists, however, does suppress feeding, meal size and weight gain in normal weight and obese rodents.
Why this rating
Based on multiple studies including genetic knockouts and pharmacological interventions.
Source
To ingest or rest? Specialized roles of lateral hypothalamic area neurons in coordinating energy balance
Juliette A. Brown et al. · Frontiers in Systems Neuroscience · 2015
DOI 10.3389/fnsys.2015.00009
narrative_reviewCited 99×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lateral hypothalamic area (LHA) neurons coordinate energy balance by integrating peripheral nutrient cues with ingestive, locomotor, and arousal behaviors.Good
- Orexin (OX) neurons in the LHA promote feeding, arousal, and physical activity, and their disruption is linked to sleep disorders like narcolepsy.Good
- Neurotensin (Nts) neurons in the LHA are implicated in coordinating anorectic stimuli and behavior to regulate hydration and energy balance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →